Loading...
XSTOCANTA
Market cap28mUSD
Dec 23, Last price  
1.72SEK
1D
-7.03%
1Q
-50.00%
Jan 2017
-72.79%
IPO
-79.75%
Name

Cantargia AB

Chart & Performance

D1W1MN
XSTO:CANTA chart
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
16.38%
Rev. gr., 5y
%
Revenues
0k
Net income
-280m
L-22.66%
-3,389,317-3,465,168-7,945,937-8,370,189-17,190,000-44,680,000-60,253,000-91,160,000-110,691,000-173,086,000-366,507,000-362,079,000-280,027,000
CFO
-287m
L-20.13%
-2,915,391-3,779,484-8,262,4866,897,877-30,277,000-39,528,000-41,103,000-104,686,000-111,254,000-156,387,000-346,445,000-358,915,000-286,664,000
Earnings
Feb 21, 2025

Profile

Cantargia AB (publ), a biotechnology company, engages in the research and development of antibody-based treatments for life threatening diseases. The company is developing CAN04, an antibody against Interleukin-1 Receptor Accessory Protein (IL1RAP) to recognize cancer cells and stimulate natural immune system to destroy such cells, as well as block the tumor inflammation that is driven by the Interleukin-1 system and is under phase IIa clinical trial; and CAN10, an antibody against IL1RAP for treatment of autoimmune and inflammatory diseases, including systemic sclerosis and myocarditis, and is under preclinical trial. It is also developing CANxx antibodies against IL1RAP. The company has collaboration agreements with Patheon Biologics BV and BioWa Inc. for the manufacture and production of CAN04; and Specialized Medical Services-oncology BV for the clinical study of CAN04. Cantargia AB (publ) was founded in 2010 and is based in Lund, Sweden.
URL
https://cantargia.com/
IPO date
Mar 17, 2015
Employees
24
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
Cost of revenue
291,216
383,342
371,464
Unusual Expense (Income)
NOPBT
(291,216)
(383,342)
(371,464)
NOPBT Margin
Operating Taxes
(9,735)
3
Tax Rate
NOPAT
(291,216)
(373,607)
(371,467)
Net income
(280,027)
-22.66%
(362,079)
-1.21%
(366,507)
111.75%
Dividends
Dividend yield
Proceeds from repurchase of equity
59,281
223,934
BB yield
-9.34%
-56.79%
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
119
24
892
Net debt
(194,747)
(426,668)
(559,386)
Cash flow
Cash from operating activities
(286,664)
(358,915)
(346,445)
CAPEX
(7,089)
(383)
Cash from investing activities
182,095
67,880
(102,429)
Cash from financing activities
54,681
223,934
3
FCF
(288,666)
(377,904)
(369,303)
Balance
Cash
194,747
426,668
559,386
Long term investments
Excess cash
194,747
426,668
559,386
Stockholders' equity
(1,507,788)
(1,233,501)
(871,850)
Invested Capital
1,676,649
1,622,867
1,404,917
ROIC
ROCE
EV
Common stock shares outstanding
169,771
128,024
100,193
Price
3.74
21.43%
3.08
-83.32%
18.46
-71.16%
Market cap
634,944
61.02%
394,314
-78.68%
1,849,563
-73.09%
EV
440,197
(32,354)
1,290,177
EBITDA
(287,766)
(379,650)
(368,018)
EV/EBITDA
0.09
Interest
6,372
4
3
Interest/NOPBT